孤独症谱系障碍及其相关医学问题的药物治疗进展

摘要/Abstract

摘要： 孤独症谱系障碍(autistic spectrum disorders,ASDs)是一种严重、复杂的神经发育性疾病,表现为一组异质性综合征。目前尚无针对其核心症状的有效治疗药物,但近年来,孤独症谱系障碍药物治疗方面的研究也取得了不少进展,经合理运用可以改善孤独症儿童的一些核心症状(如社交沟通功能、重复刻板行为、自伤行为等)以及相关医学问题(如睡眠障碍、胃肠道功能紊乱等),提高孤独症谱系障碍患儿及其家庭的生活质量。

中图分类号:

R749.94

周秉睿综述, 徐秀审校. 孤独症谱系障碍及其相关医学问题的药物治疗进展[J]. 中国儿童保健杂志, 2012, 20(4): 343-346.

参考文献

[1] Hollander E,Phillips A,Chaplin W,et al.A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism[J].Neuropsychopharmacology,2005,30(3):582-589.
[2] Chez MG,Aimonovitch M,Buchanan T,et al.Treating autistic spectrum disorders in children:Utility of the cholinesterase inhibitor rivastigmine tartrate[J].Journal of Child Neurology,2004,19(3):165-169.
[3] Chez MG,Buchanan TM,Becker M,et al.Donepezil hydrochloride:a double-blind study in autistic children[J].Pediatric Neurology,2003,1(1):83-88.
[4] Chez Michael G,Burton Q,Dowling T,et al.Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders:an observation of initial clinical response and maintenance tolerability[J].Journal of Child Neurology,2007,22(5):574-579.
[5] King BH,Wright DM,Handen BL,et al.Double-blind,placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder[J].Am Acad Child Adolesc Psychiatry,2001,40(6):658-665.
[6] Posey DJ,Kem DL,Swiezy NB,et al.A pilot study of D-cycloserine in subjects with autistic disorder[J].American Journal of Psychiatry,2004,161(11):2115-2117.
[7] Mehta MV,Gandal MJ,Siegel SJ.mGluR5-Antagonist Mediated Reversal of Elevated Stereotyped,Repetitive Behaviors in the VPA Model of Autism[J].Plos One,2011,6(10):e26077.
[8] Gogolla N,Leblanc JJ,Quast KB,et al.Common circuit defect of excitatory-inhibitory balance in mouse models of autism[J].J Neurodev Disord,2009,1(2):172-181.
[9] Erickson CA,Ginsberg LD,Rathmell B,et al.Results of an 8-week,open-label trial of STX209 (arbaclofen) in autism spectrum disorders:social and communicative function.36th Annual Meeting of the American-Neurological-Association (ANA)[J].Annals of Neurology,2011,70(15S):145-150.
[10] Hagerman R,Rathmell B,Wang LL,et al.Targeted treatment for fragile X syndrome:results of a randomized controlled phase II trial of arbaclofen[J].Journal of Intellectual Disability Research,2010,54:884-890.
[11] Research Units on Pediatric Psychopharmacology (RUPP) Autism Network.Randomized,controlled,crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity [J].Arch Gen Psychiatry,2005,62(11):1266-1274.
[12] Arnold LE,Aman MG,Cook AM,et al.Atomoxetine for hyperactivity in autism spectrum disorders:placebo-controlled crossover pilot trial[J].J Am Acad Child Adolesc Psychiatry,2006,45(10):1196-1205.
[13] Barnard L,Young AH,Pearson J,et al.A systematic review of the use of atypical antipsychotics in autistic disorder[J].Psychopharmacol,2002,16:93-101.
[14] Research Units on Pediatric Psychopharmacology Autistic Disorder Network.Risperidone in children with autistic disorder and serious behavioral problems[J].N Engl J Med,2002,347:314-321.
[15] Handen BL,Sahl R,Hardan AY.Guanfacine in children with autism and/or intellectual disabilities[J].J Dev Behav Pediatr,2008,29(4):303-308.
[16] Posey DJ,Puntney JI,Sasher TM,et al.Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders:a retrospective analysis of 80 cases[J].J Child Adolesc Psychopharmacol,2004,14:233-241.
[17] Hardan AY,Handen BL.A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder[J].J Child Adolesc Psychopharmacol,2002,12:237-241.
[18] Marcus RN,Owen R,Kamen L,et al.A placebo-controlled,fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder[J].J Am Acad Child Adoles Psychiatry,2009,48(11):1110-1119.
[19] Owen R,Sikich L,Marcus RN,et al.Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder[J].Pediatrics,2009,124(6):1533-1540.
[20] Elchaar GM,Maisch NM,Augusto LM,et al.Efficacy and safety of naltrexone use in pediatric patients with autistic disorder[J].Annals of Pharmacotherapy,2006,40(6):1086-1095.
[21] Chez MG,Chang M,Krasne V,et al.Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005[J].Epilepsy Behav,2006,8(1):267-271.
[22] Eriksson AS,Knutsson E,Nergardh A.The effect of lamotrigine on epileptiform discharges in young patients with drug-resistant epilepsy[J].Epilepsia,2001,42:230-236.
[23] Ronen GM,Richards JE,Cunningham C,et al.Can sodium valproate improve learning in children with epileptiform bursts but without clinical seizures? [J].Dev Med Child Neurol,2000,42:751-755.
[24] Wirojanan J,Jacquemont S,Diaz R,et al.The efficacy of melatonin for sleep problems in children with autism,fragile X syndrome,or autism and fragile X syndrome[J].J Clin Sleep Med,2009,5:145-150.
[25] Wasdell MB,Jan JE,Bomben MM,et al.A randomized,placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities[J].J Pineal Res,2008,44(1):57-64.
[26] Wirojanan J,Jacquemont S,Diaz R,et al.The efficacy of melatonin for sleep problems in children with autism,fragile X syndrome,or autism and fragile X syndrome[J].J Clin Sleep Med,2009,5:145-150.
[27] Richard EF,Daniel AR.Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders[J].Pediatric Research,2011,69(5):41-47.
[28] Andrew WZ,Harumi J.The immune system's role in the biology of autism,cerebrospinal fluid and serum markers of inflammation in autism[J].Pediatr Neurol,2005,33:195-201.